Pregabalin
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Pregabalin: From Unspecified Original Indication to Tendinitis
One-Sentence Summary
Pregabalin (DrugBank DB00230) is a gabapentinoid analgesic/anticonvulsant; this Evidence Pack does not record its original approved indication(s) — that field is empty in the source data. The TxGNN model predicts it may be effective for Tendinitis, but current support is limited to 0 clinical trials and 6 publications, most of which address postoperative pain control rather than tendinitis pathology itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in evidence pack (data gap) |
| Predicted New Indication | Tendinitis |
| TxGNN Prediction Score | 99.71% |
| Evidence Level | L4 |
| Taiwan Market Status | Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for pregabalin is not available in this Evidence Pack, and no original indication is recorded either — both are flagged as data gaps (MOA: High severity; TFDA label/warnings: Blocking severity). Based on general pharmacological class knowledge represented in the literature evidence below, pregabalin acts on the α2δ subunit of voltage-gated calcium channels to reduce neuronal excitability and is used clinically as an analgesic for neuropathic and postoperative pain.
The link to tendinitis is indirect. Most of the supporting literature examines pregabalin's use for postoperative pain control after rotator cuff/shoulder arthroscopy or for unrelated peripheral neuropathy case reports, not for tendinitis pathology (inflammation or collagen repair) itself. As the model's own repurposing rationale states, pregabalin's analgesic effect may only indirectly relieve neuropathic pain that co-occurs with tendinitis, but there is no disease-specific mechanistic evidence connecting it to tendon pathology.
Given this, the prediction should be read as a pain-management adjacency signal rather than a disease-modifying hypothesis for tendinitis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32839073 | 2021 | RCT | J Orthop Sci | Retrospective cohort on pregabalin's analgesic efficacy and opioid-sparing effect after arthroscopic rotator cuff repair |
| 34052386 | 2022 | RCT | Arthroscopy | Perioperative oral pregabalin produced pain scores equivalent to interscalene brachial plexus block after rotator cuff repair |
| 40818536 | 2025 | Editorial Commentary | Arthroscopy | Discussion of piriformis syndrome diagnosis/treatment; not pregabalin- or tendinitis-specific |
| 37051935 | 2023 | Case report | Pain Practice | Posterior femoral cutaneous nerve impingement from hamstring tendonitis in a marathon runner |
| 41017607 | 2025 | Case report | Praxis | Fluoroquinolone (ciprofloxacin)-associated tendinopathy and disability; not a pregabalin study |
| 39703364 | 2024 | Animal study (non-pregabalin agent) | Adv Pharmacol Pharm Sci | Plant extract (Cissus quadrangularis) attenuates chemotherapy-induced neuropathy in rats; tendon healing mentioned only as background |
Taiwan Market Information
Pregabalin is currently not marketed in this jurisdiction (0 authorizations on record), so no product license table is available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for pregabalin in tendinitis is at Evidence Level L4 with no clinical trials, and the available literature addresses postoperative pain management or unrelated conditions rather than tendinitis pathology directly — insufficient to justify advancing past initial screening.
To proceed, the following is needed:
- Confirmed original indication(s) and detailed MOA data (currently data gaps)
- TFDA package insert (warnings/contraindications) — currently a Blocking data gap for safety screening
- Preclinical or mechanistic studies directly evaluating pregabalin in tendinopathy models
- A disease-specific pilot or observational study before considering trial design
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.